复星医药(02196.HK)复方匹可硫酸钠颗粒上市申请获批

阿斯达克财经
27 Feb

复星医药(02196.HK) 公布,控股子公司苏州二叶制药就复方匹可硫酸钠颗粒的上市注册申请,已于近日获国家药品监督管理局批准。该药品为复星医药自主研发的化学药品,主要用于结肠镜检查、X光检查前的肠道清洁准备,用于必要时在外科手术前清洁肠道。

截至2025年1月,集团现阶段针对该药品累计研发投入约为853万元人民币。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10